

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number  
**WO 03/053488 A1**

(51) International Patent Classification<sup>7</sup>: **A61L 27/02**,  
27/10, 24/02

(21) International Application Number: PCT/SE02/02428

(22) International Filing Date:  
20 December 2002 (20.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0104359-5 20 December 2001 (20.12.2001) SE  
60/341,282 20 December 2001 (20.12.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **BONE SUPPORT AB** [SE/SE]; Växthuset Forskningsbyn IDEON, Ole Römers väg 12, S-223 70 Lund (SE).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **LIDGREN, Lars** [SE/SE]; Bredgatan 9B, S-221 21 Lund (SE).

(74) Agent: **STRÖM & GULLIKSSON IPC AB**; P.O. Box 4188, S-203 13 Malmö (SE).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/053488 A1

(54) Title: A NEW BONE MINERAL SUBSTITUTE

(57) Abstract: The invention refers to an artificial bone mineral substitute material which comprises at least one ceramic and at least one water soluble non-ionic X-ray contrast agent. The invention refers to a composition for producing the same, which further comprises an aqueous liquid, as well as the use of the composition as a X-ray contrast medium.

### A NEW BONE MINERAL SUBSTITUTE

The invention refers to an artificial bone mineral substitute material as well as a composition for the same, which have improved radio-opacity. The invention also refers to the use of composition for an artificial bone mineral substitute material as an X-ray contrast medium.

The life expectancy of the world population has increased tremendously during the last 50 years. Our population is living longer than ever. The next ten years, it has been forecasted that there will be more people over 60 years of age than less than twenty years of age in Europe. More people will need medical help for diseases related to age, which will increase the pressure of the hospitals.

Bone is the second most common material to be transplanted after blood. The most reliable method to repair bone defects is to use autogenous bone, i.e. bone taken from another site in the body. Autografts are osteogenic, i.e. derived from or composed of any tissue which is concerned with the growth or repair of bone. However, problems may occur at the second surgical site where the graft is taken. To avoid this extra trauma allografts can be used, i.e. bone graft between individuals of the same species. Allografts have a lower osteogenic capacity than autografts and the rate of new bone formation might be lower. They also have a higher resorption rate, a larger immunogenic response and less revascularisation of the recipient. Allografts must also be controlled for viruses since they can transfer, for example, HIV and hepatitis. The use of allografts is now the most common method for bone transplantation and repairing of bone defects.

The problems with using autografts and the limited supply of bones at most hospitals has led to a lot of research in materials that can be used as bone substitutes. The ideal bone substitute should be biocompatible, inject-

able through a needle, self-setting, osteoconductive, resorbable and replaced by new normal bone.

An injectable bone graft substitute can improve the treatment of osteoporosis. Osteoporosis is a disease that acts upon older people. Bone is live tissue, new cells are formed and some cells die daily. In a year 10-30 % of our entire skeleton is remodeled. Osteoporosis leads to a total skeleton mass reduction because of a non-equilibrium state between cells that form bone (osteoblasts) and cells that resorb bone (osteoclasts). When the resorption rate of bone is higher than the rate of bone formation it leads to a total reduction of bone. The skeleton becomes weaker and finally a fracture occurs either by reason of a fall or just because the skeleton can not withstand the weight of the body. When the spine becomes weaker it will be curved and compressed.

There are two types of bone: trabecular and cortical. The outside layer of bone usually consists of cortical bone, which is very dense and solid, trabecular bone is much more porous and is found inside of the bones. Osteoporosis initially effects the trabecular bone.

Fractures resulting from osteoporosis are very troublesome to treat. The skeleton is fragile and difficult to stabilise with screws and plates. Even if the screw insertion succeeds it often becomes loose when the patient later starts to move. To attach the screws to the bone a bone graft substitute can be injected in the drilled holes before screw insertion. The result is that the screw fixation improves and the patient recovers faster with less pain. If a thin layer of bone substitute is used it can be difficult to see in an X-ray picture. To improve the visibility, it could be possible to add a radiographic contrast medium to the material. To stabilise the spine, a bone graft substitute can be injected. If a bone substitute leaks from the spine, it will cause pressure on nearby

tissues and nerves which will cause pain and eventually nerve injury.

One of the materials that has been used for stabilising the spine is the bone cement polymethylmetacrylate (PMMA). PMMA is a chain polymer that is glassy at room temperature. PMMA is a good material for intraocular lenses and hard contact lenses. It is also used to fixate the metal implant in hip joints and for skull defect reconstruction and vertebroplasty. PMMA is not resorbed in the bone. PMMA has a couple of drawbacks. For example PMMA cures with a strongly exothermic reaction, potentially damaging adjacent soft tissue structures i.e. cell death, particularly in the event of cement extrusion. Therefore, PMMA is not an optimal material for this indication.


Presently, mainly three kinds of bone substitutes are used for repairing bone: calcium phosphate, hydroxyapatite and calcium sulfate.

Calcium phosphates are suitable as bone substitutes because of their bioactive properties, i.e. having an effect on or obtaining response from living tissue. They have low fatigue properties relative to bone and can only be used in non-weight bearing areas. Their resorption rate is relatively slow, at least six months.

There are two different categories of calcium phosphates: CaP obtained by precipitation from an aqueous solution at room temperature (low-temperature CaP) and CaP obtained by a thermal reaction (high-temperature CaP). The calcium phosphates used in medicine are high-temperature CaP, for example  $\alpha$ -tricalcium phosphate ( $\alpha$ -TCP) and hydroxyapatite (HA). Low-temperature CaP is used to synthesize high-temperature CaP.

Tricalcium phosphate ( $\text{Ca}_3(\text{PO}_4)_2$ ) exists in two forms:  $\alpha$ -TCP and  $\beta$ -TCP. The crystal structure of  $\alpha$ -TCP is monoclinic and consists of columns of cations while the  $\beta$ -TCP has a rhombohedral structure.  $\beta$ -TCP is stable up to 1180 °C

and  $\alpha$ -TCP is stable between 1180-1470°C.  $\alpha$ -TCP forms by heating  $\beta$ -TCP above 1180 °C and quenching it to retain its structure.  $\alpha$ -TCP is less stable than  $\beta$ -TCP and forms the stiffer material calcium-deficient HA when mixed with  
5 water, see formula 2.1.



Hydroxyapatite is the most stable calcium phosphate  
10 and the primary non-organic component of bone. Most of the bone graft substitutes on the market are made of hydroxyapatite. HA is highly crystalline and the least soluble of the calcium phosphates.

Hydroxyapatite and tri-calcium phosphate are the most  
15 common calcium phosphates used to fill bone defects and as implant coatings. They have low fatigue properties relative bone and can only be used in non-weight bearing areas. Their resorption rate is relatively slow, from six months to several years. It is possible to increase the rate of  
20 degradation slightly by increasing the surface area of the material, decreasing the crystallinity and the crystal perfection and decreasing the size of crystals and grains in the material. A higher resorption rate can be preferable to encourage bone formation.

25 Hydroxyapatite ( $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ ) is the major mineral component of bone. Artificial hydroxyapatite (HA) has a chemical and crystallographic structure similar to the natural HA of bone and has been studied as a bone replacement material for over 30 years. HA is highly crystalline  
30 and the most stable CaP in an aqueous solution. HA is the least soluble calcium phosphate at pH over 4.2, which means that other calcium phosphates with a pH over 4.2 will tend to dissolve and form precipitated HA. HA is biocompatible, not osteogenic but has osteoconductive properties. Most of  
35 the bone substitutes on the market are made of HA. They are regarded as degradable, but their degradation time is very

long. The final compressive strength depends on which type of HA is used. If spray-dried HA is used the compressive strength is very low. Even the shape and size of the powder affect the mechanical strength.



5        There are several forms of HA that have been used experimentally and clinically: solid ceramic blocks, porous blocks and solid and porous particulate. The major use of HA is in the oral surgery, where the particulate HA is used. Particulate HA is inconvenient to use for orthopaedic  
10 applications because particles often migrate from the implant site before bone ingrowth secure them in place. Porous HA blocks have successfully been used for cranio-facial reconstructions and orthopaedic applications, but they are difficult to shape.

15        Research in calcium sulfates as a bone graft substitute has been carried out for more than a century. Several investigators have reported experiments using calcium sulfate hemihydrate, commonly known as Plaster of Paris (PoP). This material is well accepted by the body the  
20 resorption rate is faster than the rate of bone ingrowth and the mechanical strength for Plaster of Paris is low.

      Calcium sulfate hemihydrate exists in two forms,  $\alpha$ -form and  $\beta$ -form. The  $\alpha$ -form has monoclinic structure and consists of compact, wellformed, and transparent large  
25 primary particles. The  $\beta$ -form has rhombohedral structure and consists of rugged secondary particles made up of extremely small crystals.

      Plaster of Paris is made from calcium sulfate dihydrate (gypsum) through dehydration, see reaction 2.2. The  
30 gypsum is ground and heated until about 75 % of the water is gone and  $\text{CaSO}_4 \cdot \frac{1}{2}\text{H}_2\text{O}$  is obtained. When Plaster of Paris is mixed with water, an exothermic reaction takes place with gypsum as product, which is called rehydration of gypsum, see reaction 2.3. The structure of gypsum consists of

layers of alternate  $\text{SO}_4^{2-}$  ions strongly bonded to  $\text{Ca}^{2+}$  and sheets of water molecules.



If calcium sulfate dihydrate is added to calcium sulfate hemihydrate the setting time will decrease because the nucleation time is eliminated. Crystal growing can start directly on the calcium sulfate dihydrate particles which thus act as an accelerator.

Disodium hydrogen phosphate ( $\text{Na}_2\text{HPO}_4$ ) is used as an accelerator for the calcium phosphate compositions. When  $\text{Na}_2\text{HPO}_4$  is added to the cement powder, the  $(\text{PO}_4)^{3-}$  ions will bond to  $\text{Ca}^{2+}$  ions and the precipitation rate will increase which gives a shorter setting time.

Research in the use of different radiocontrast materials in bone cement, i.e. PMMA, has been conducted and the influence of radiocontrast media in PMMA has been studied. The radiocontrast agents, bariumsulfate ( $\text{BaSO}_4$ ) and zirconium dioxide ( $\text{ZrO}_2$ ), are commonly added to polymethylmethacrylate (PMMA) to ensure X-ray visibility and to ease radiological assessments. These two materials have negative side effects in that they may cause pathological bone resorption as well as cause damage to the articulating surface if they enter the joint space, a marked increase in the production of polyethylene wear debris being obtained. Furthermore, if included in bone substitutes, such an X-ray dense bone substitute may leak from the spine and cause nerve damages.

When such a ceramic bone is resorbed with time, it will subsequently contact other tissues. Contrast agents in the form of metals, zirconium oxide, or barium sulfate will remain at the site of treatment or will be spread as small

particles to other organs, such as the lungs, and/or will ultimately be transported to the kidneys where they will be trapped. Thus, it is important that the contrast agent dissolves in the blood and is disposed of via the kidneys  
5 as primary urine.

Water soluble non-ionic X-ray contrast agents have been used in connection with polymeric materials. In WO 99/62570 such agents have been used for preventing the release of particles from the bone cement, i.e. the plastic  
10 material, which contribute to the wear of adjacent surfaces at the surgical site.

The object of this invention is to provide an artificial bone mineral substitute material, whereby the above-mentioned problems are eliminated or reduced.

15 Another object of the invention is to provide an artificial bone mineral substitute material which exhibits positive radiophysical effects in comparison with the state of the art.

Still another object is to provide a bone graft substitute which improves the possibility to detect leakage  
20 during the operation.

A further object of the invention is to provide a composition which after hardening results in a "safe" ceramic implant comprising a biocompatible X-ray contrast  
25 medium, whereby a leakage of the contrast agent from the site of injection is allowed, which does not give rise to inflammation in the vicinity of the site of injection and is thus atoxic for e.g. the nervous system.

Yet a further object is to provide a composition  
30 which does not exhibit the drawbacks of high viscosity at delivery and which provides improved rheological properties and allows injection at distant sites in comparison with the state of the art.

Still a further object of the invention is to provide a composition, whereby ceramic materials do not have to be included in the X-ray contrast medium.

Still another object of the invention is to provide a  
5 composition, whereby it is possible to follow the healing of bone defects and bone fractures.

Still yet a further object of the invention is to provide a composition which can be used in applications of bone defects communicating with joints.

10 These objects as well as other objects that will be apparent from the following description are accomplished by the artificial bone mineral substitute material as well as the composition for the same as claimed.

In the drawings

15 FIG 1 shows the relation between injection time and amount of iohexol for a constant amount of accelerator for a calcium sulfate based composition;

FIG 2 shows the relation between injection time and amount of iohexol for calcium phosphate based compounds;  
20 and

FIG 3 shows the relation between setting time and amount of iohexol for a calcium phosphate compound with a liquid/powder ratio of 0.28.

The inventive composition as well as the inventive  
25 artificial bone mineral substitute material comprises at least one ceramic material and at least one water soluble non-ionic X-ray contrast agent. It is preferred that the composition is injectable and that the artificial bone obtained is bioresorbable.

30 Suitable conventional water soluble non-ionic X-ray contrast agents are iodinated aromatic compounds, which have one or several aromatic nuclei that are at least triiodo-substituted. Such agents are shown in US 5,695,742 and comprise CAS (Chemical Abstract Service) registration  
35 numbers 31112-62-6 (metrizamide), 60166-93-0 (iopamidol),

78649-41-9 (iomeprol), 73334-07-3 (iopromide), 877771-40-2 (ioversol), 66108-95-0 (iohexol), 89797-00-2 (iopentol), 107793-72-6 (ioxilan), 99139-49-8 (II-1), 75751-89-2 (iogulamide), 63941-73-1 (iogluco), 63941-74-2 (iogluco-  
5 amide), 56562-79-9 (iogluconide), 76984-84-0 (MP-7011), 64965-50-0 (MP-7012), 77111-65-0 (MP-10007), 79944-49-3 (VA-7-88), 79944-51-7 (also shown in EP 033426), 79211-10-2 (iosimide), 79211-34-0 (iocibidol), 103876-29-5 (also shown in EP 0177414), 141660-63-1 (iofratol), 92339-11-2 (iodi-  
10 xanol), 79770-24-4 (iotrol), 71767-13-0 (iotasul), 81045-33-2 (iodecol), 143200-04-8 (also shown in WO 92/086), 143199-77-3 (also shown in WO 92/08691), 143200-00-4 (also shown in WO 92/08691), 78341-84-1 (also shown in US 4348377), 122731-47-9 (also shown in EP 0308364),  
15 122731-49-1 (also shown in EP 0308364), 99139-65-8 (also shown in WO 85/01727), 99139-62-5 (also shown in WO 85/01727), and 78341-84-1 (also shown in EP 0023992).

Other such water soluble non-ionic X-ray contrast agents are shown in US 5,447,711 and comprise iotrolan,  
20 ioxaglate, iodecimol, and iosarcol. Other suitable contrast agents are iotusal, ioxilane, and iofrotal.

Preferably, the water soluble non-ionic X-ray contrast agent has a low osmolarity such as iohexol, iodixanol, ioversol, iopamidol, and iotrolane.

25 For example, iohexol ( $C_{19}H_{26}I_3N_3O_9$ ) as well as its dimer iodixanol can with advantage be used as a water soluble non-ionic X-ray contrast agent. These substances do not influence bone formation and they have a good biocompatibility in bone. They are used for different  
30 purposes in medicine. For example it can be used for patients with kidney failure to determine the rate of plasma clearance by the kidney.

Thus, the inventive composition as well as the inventive artificial bone mineral substitute material comprises at least one water soluble non-ionic X-ray contrast  
35

agent, preferably iohexol or its dimer iodixanol. When used in the inventive composition, the water soluble non-ionic X-ray contrast agent should have a concentration between 2 and 20 weight% of the total weight of the powder components in the same.

Of course, other contrast agents can also be included in the inventive artificial bone mineral substitute material as well as the composition for the same.

Suitable ceramics are calcium sulfates and calcium phosphates.

Examples of calcium phosphate ceramics are  $\alpha$ -tricalcium phosphate, hydroxyapatite, dicalcium phosphate dihydrate, anhydrous dicalcium phosphate, tetracalcium phosphate,  $\beta$ -tricalcium phosphate, calcium-deficient hydroxyapatite, monocalcium phosphate monohydrate, monocalcium phosphate, calcium pyrophosphate, precipitated hydroxyapatite, carbonated apatite (dahlite), octocalcium phosphate, amorphous calcium phosphate, oxyapatite, and carbonatoapatite.

Suitable types of calcium phosphates are shown in Table 1 below.

Ca/P	Calcium phosphate	Formula
1.35	Amorphous calcium phosphate I ACP	-
1.35	Amorphous calcium phosphate II ACP	-
0.5	Monocalcium phosphate monohydrate MCPM	$\text{Ca}(\text{H}_2\text{PO}_4)_2 \cdot 2\text{H}_2\text{O}$
1.0	Dicalcium phosphate dihydrate DCPD (brushite)	$\text{CaHPO}_4 \cdot 2\text{H}_2\text{O}$
1.33	Octocalcium phosphate	$\text{Ca}_8(\text{HPO}_4)_2(\text{PO}_4)_4 \cdot 5\text{H}_2\text{O}$
1.5	Calcium deficient hydroxyapatite (CDHA)	$\text{Ca}_9(\text{HPO}_4)(\text{PO}_4)_5(\text{OH})$
1.5	Tricalcium phosphate (TCP)	$\text{Ca}_3(\text{PO}_4)_2$
1.67	Hydroxyapatite (HA)	$\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$

Preferably, the calcium phosphate has a Ca/P-ratio between 0.5 and 2. Likewise, it is preferred that the particulate calcium phosphate is hydroxyapatite (HA), tri-calcium-phosphate (TCP), or a mixture thereof.

5 In the composition the particulate calcium phosphate should have a particle size of less than 20  $\mu\text{m}$ , preferably less than 10  $\mu\text{m}$ .

The calcium sulfate can be calcium sulfate  $\alpha$ -hemihydrate, calcium sulfate  $\beta$ -hemihydrate, or calcium sulfate  
10  $\beta$ -dihydrate.

Calcium carbonate can also be used as a ceramic.

The inventive composition for an artificial bone mineral substitute material can in itself be used as an X-ray contrast medium. An additive X-ray effect is obtained  
15 by means of the composition according to the invention, since the X-ray contrast ability of its ceramic component is utilized. The inclusion of at least one water soluble non-ionic X-ray contrast agent in the composition increases the original X-ray density of the X-ray dense bone substi-  
20 tute. Thus, no further ceramic radio contrast agents, such as bariumsulfate and zirconium dioxide, have to be included in the composition for an artificial bone mineral substitute material according to the invention. Such hard ceramic particles will wear joints when torn off from the bone sub-  
25 stitute. In the joints they will cause physical damage and eventually result in inflammatory reactions.

Thus, the inventive composition, which comprises at least one water soluble non-ionic X-ray contrast agent, can be injected adjacent to joints, and the resulting artifi-  
30 cial bone mineral substitute material can be used for bone defects communicating with joints. Such applications include the repair of osteochondral joints defects as well as fractures or bone defects involving a joint.

In addition, the dual origin of X-ray density can  
35 be further exploited, for example in order to follow the

healing process after implantation of the inventive composition in a human or animal body. When the obtained artificial bone mineral substitute material, which comprises at least one water soluble non-ionic X-ray contrast agent, is replaced by ingrowing bone, the water soluble agent will slowly disappear. This results in a progressive decline in X-ray density, which can be monitored.

In order to increase the healing process the inventive composition should also comprise at least one osteogenic factor. In this connection an osteogenic factor is a substance that influences bone turnover, either by increasing bone formation or by decreasing bone breakdown.

Suitable bone inducing (stimulating and/or accelerating) substances are growth factors and hormones. Growth factors and derivatives thereof are preferred, which are locally acting, e.g. the BMP family (Bone Morphogenetic Proteins). It is also preferred to use autologous growth factors in order to accelerate bone growth.

Examples of such bone stimulating compounds are parathyroid hormones and derivatives thereof, estrogens, progesterones, androgens, testosterone, calcitonin, somatomedin, and oxytocin.

The enamel matrix proteins amelin-1, amelin-2 and ameloblastin as well as the cholesterol-lowering compound statin can also be included in order to induce, stimulate and/or accelerate bone formation.

Examples of suitable bone breakdown inhibitors are biphosphonates, osteocalcin, osteonectin and derivatives thereof, which can be included in the inventive composition and the resulting material.

The inventive composition may also include at least one accelerator, which preferably is calcium sulfate dihydrate and/or disodium hydrogen phosphate. When calcium sulfate dihydrate is used, it should have a concentration

between 0.1 and 10 weight% of the total weight of the powder components in the composition.

A preferred injectable composition comprises particulate calcium sulfate hemihydrate, particulate calcium phosphate. The composition may also include particulate calcium sulfate dihydrate as an accelerator and optionally vitamin E. When vitamin E is included, it should have a concentration between 0.1 and 10 weight% of the total weight of the powder components in the composition.

Likewise, the inventive composition as well as the resulting artificial bone mineral substitute material may further include calciferols, calcitriols, as well as other D vitamins and derivatives thereof. These compounds help to regulate calcium metabolism and normal calcification of the bones in the body as well as influence the utilization of mineral phosphorus.

Compounds with static or cidal effects against invading foreign living material can also be included. Such compounds include natural antibiotics as well as other semisynthetic and synthetic antibacterial compounds, antiviral compounds, antifungal compounds, and antiparasite compounds.

Cytostatics and other chemotherapy substances can also be included in the composition as well as the material according to the invention.

When at least one powdered ceramic is a calcium sulfate hemihydrate and at least one of hydroxyapatite and  $\beta$ -tricalcium phosphate, the at least one of hydroxyapatite and  $\beta$ -tricalcium phosphate has a concentration between 20 and 60 weight% of the total weight of the powder components in the inventive composition.

When at least one powdered ceramic is a calcium sulfate hemihydrate and  $\alpha$ -tricalcium phosphate, the calcium sulfate hemihydrate has a concentration between 1 and 30 weight% and the  $\alpha$ -tricalcium phosphate has a concentra-

tion between 50 and 99 weight% of the total weight of the powder components in the inventive composition, respectively

Other injectable compositions for an artificial bone mineral substitute material are similarly based on tetracalciumphosphate (TTCP) and hydroxyapatite (HA);  $\alpha$ -tricalcium phosphate (TCP) and tetracalciumphosphate;  $\alpha$ -tricalcium phosphate, tetracalciumphosphate, and citric acid;  $\alpha$ -tricalcium phosphate, tetracalciumphosphate, dicalcium sulfate dihydrate (DCPD), and hydroxyapatite;  $\alpha$ -tricalcium phosphate, dicalcium phosphate (DCP), calcium carbonate, and hydroxyapatite; and hydroxyapatite acrylic monomers.

By including a water-soluble non-ionic X-ray contrast agent the strength of the bone mineral substitute is somewhat decreased. This can, however, be compensated by reducing the water content thereof. Nevertheless, the inventive artificial bone mineral substitute material is preferably used in connection with indications, in which a high strength is not required but when a high X-ray contrast is required.

An additional advantage of the artificial bone mineral substitute material according to the invention is that the water soluble non-ionic X-ray contrast agent also functions effectively in its solid dry state. Thus, the water-soluble non-ionic X-ray contrast agent is mixed into the inventive composition as well as the inventive artificial bone mineral substitute material and is evenly distributed in the same.

Preferably, the water soluble non-ionic X-ray contrast agent is mixed into the dry sulfate component as a dry powder, or it is dissolved in the aqueous liquid of the composition. It is also preferred that the aqueous liquid component is distilled water.

In the composition according to the invention a ratio between the powder components and the aqueous liquid component, i.e. the liquid/powder ratio, should be between 0.1 and 0.4 ml/g.

5 In a preferred embodiment of the inventive injectable composition, which comprises calcium sulfate hemihydrate, calcium phosphate, and an aqueous liquid, the water is allowed to react with the dry sulfate or phosphate components of the composition. This results in a crystallization of  
10 the ceramic component(s).

When the artificial bone mineral substitute material is resorbed in the body, the water in the blood will ultimately dissolve the sulfate ceramic and the water soluble non-ionic X-ray contrast agent will be released and dis-  
15 posed of.

Likewise, in a mixture of sulfate/phosphate or sulfate/hydroxyapatite, the water soluble non-ionic X-ray contrast agent will be dissolved in a more limited extent since it will be locked within the bone mineral substitute  
20 material.

For example, a composite of hydroxyapatite and calcium sulfate results in a material with much better handling properties than hydroxyapatite alone. The mixture can be injected or manually inserted to a bone defect under  
25 pressure. The hydroxyapatite particles are held in place by the Plaster of Paris which initially acts as a binder. When the Plaster of Paris resorbs, a matrix with controlled porosity is obtained, which supports bone ingrowth. If the amount of hydroxyapatite is at least 40 %, the temperature  
30 of the setting reaction is decreased which is another reason for adding hydroxyapatite to Plaster of Paris.

Thus, by mixing the water soluble non-ionic X-ray contrast agent as a powder in the dry sulfate or phosphate component, respectively, the dissolution of the same with  
35 time can be controlled.

The very viscous bone substrate is more easily injected than those according to the state of the art, i.e. positive rheological properties are obtained when a water soluble non-ionic X-ray contrast agent is included in the composition for a bone mineral substitute material.

#### EXAMPLES

The invention will now be further described and illustrated by reference to the following examples. It should be noted, however, that these examples should not be construed as limiting the invention in any way.

##### *Example 1. X-ray analysis.*

The X-ray visibility was determined with three different amounts of iohexol in both calcium phosphate and calcium sulfate based compositions. Two different tests were performed. In one test the samples used for setting tests were subjected to X-rays and the visibility of the three samples were compared. Four samples of each material were studied. The liquid/powder ratio was the same for the three tests. In the other test, holes were drilled in bovine vertebrae. The holes were 10 mm in diameter and the depth was 10 mm. The holes were filled with material by injection through a syringe and analysed by X-ray. The visibility of the different materials was compared with the visibility of bone. The X-ray settings were 60kV and 40mAs. The same equipment was used for both tests. Table 2 shows the compositions based on calcium sulfate hemihydrate, and in Table 3 the compositions based on calcium phosphate are shown. An aluminium ladder scaled from 1-5 was used for the comparison, 5 being the lowest visibility and 1 the highest.

Table 2

IoHexol (wt%)	PoP (wt%)	HA (wt%)	Accelerator (wt%)	Liquid/powder ratio
10	53.28	36	0.72	0.21
5	56.24	38	0.76	0.21
0	59.2	40	0.8	0.21

Table 3

IoHexol (wt%)	TCP (wt%)	PoP (wt%)	Calcium sulfate dihydrate (wt%)	Liquid/powder ratio
10	70	19.8	0.2	0.28
5	75	19.8	0.2	0.28
0	80	19.8	0.2	0.28

It was found that the X-ray visibility was improved by adding a radio-contrast medium, such as ioHexol or its dimer iodixanol. A concentration of 10 % ioHexol makes the visibility significantly better both in calcium phosphates and calcium sulfates compared to bone. There is no difference between the visibility in calcium phosphates and calcium sulfates.

#### Example 2. Test of Injectability.

An Instron 8511.20 equipment was used. Twenty gram of each powder was mixed with distilled water and added to a 10 ml syringe with a 2 mm diameter opening. The syringe was placed in the Instron machine and compressed at a constant rate of 10 mm/min. For injection of the paste by hand, the maximum force corresponds to about 120 N. The Injection time was calculated as the time from start mixing powder and liquid until the force is more than 120 N. The final value for the injection time was taken as a mean value of six tests. For clinical applications, the required injection time is 3 to 8 minutes.

The use of the inventive composition for an artificial bone mineral substitute material as an

injectable X-ray contrast medium was tested. Three samples of a contrast medium with or without a water soluble non-ionic X-ray contrast agent were tested, the total injection time as well as the weight extruded from syringe being measured. The results are shown in Table 4 below.

Table 4

Contrast medium	Total injection time (min)	Weight extruded from syringe (%)
Water (deionized) L/P=0.28		
Sample 1	4.23	22
2	4.17	20
3	4.28	16
Iohexol 10.0% L/P=0.326 H <sub>2</sub> O/P=0.28		
Sample 1	6,28	77
2	6,77	68
3	6,78	69

The utility, i.e. the injectability, of the contrast medium is markedly increased after the inclusion of the water soluble non-ionic X-ray contrast agent.

Further material compositions tested for injection time are shown in Table 5 and 6. In Table 5 the compositions based on calcium sulfate hemihydrate are shown, which were tested for in injection time tests. Table 6 shows the corresponding compositions based on calcium phosphate.

Table 5

20

Iohexol (wt%)	PoP (wt%)	HA (wt%)	Accel. (wt%)	Liquid/powder ratio
10	53.64	36	0.36	0.21
10	53.28	36	0.72	0.21
10	52.92	36	1.08	0.21
5	56.62	38	0.38	0.21
0	59.6	40	0.4	0.21

Table 6.

Iohexol (wt%)	$\alpha$ -TCP (wt%)	PoP (wt%)	Calcium sulfate dihydrate (wt%)	Liquid/powder ratio
10	70	19.8	0.2	0.26
5	75	19.8	0.2	0.26
0	80	19.8	0.2	0.26

With calcium sulfate hemihydrate as a ceramic the  
5 injection time was found to be dependent on the amount of  
iohexol or its dimer iodixanol. The influence of iohexol  
was investigated in the same way, 0, 5 and 10 % of iohexol  
were tested with a constant amount of accelerator. The  
tests showed that an increase in amount of iohexol in-  
10 creases the injection time, see FIG 1.

In addition, iohexol increases the injection time  
when calcium phosphosphate is used as a ceramic, see FIG 2.

#### Example 3. Test of Setting.

15 To determine the time of setting the ASTM standard  
test method by Gillmore needles has been used. The Gillmore  
apparatus consists of two needles with different weights  
applied. The initial needle has a diameter of  $2,12 \pm 0,05$   
mm and a weight of  $113 \pm 0,5g$  is applied. The final needle  
20 has a diameter of  $1.06 \pm 0.05$  mm and a weight of  $453.6$   
 $\pm 0.5g$ .

To prepare test specimens the iohexol is first dis-  
solved in distilled water and then added to the powder  
mixture. 10 gram of powder, with the iohexol included was  
25 used in each test. After mixing the paste is put into two  
moulds to form the test specimens. The initial and final  
setting time was taken as a mean value of the two tests.  
This procedure was repeated six times. The result presented  
is the mean value of the six tests.

30 The initial setting time is the time from the moment  
water is added to the bone substitute powder until the

initial needle leaves no mark on the surface of the specimen. The final setting time is the time required for the paste to set so much that the final needle leaves no mark on the surface.

- 5       The ultimate amount of HA is 40 wt% if a mixture of PoP, HA and accelerator is used. Therefore the amount of HA is related to PoP and the accelerator. When materials with 0, 5, 10 wt% of iohexol were tested the iohexol was first calculated and then 40 % HA and for example 0,4 wt% accel-
- 10       erator and 59,6 wt% PoP of the rest were used. The compositions of the tested materials are shown in Table 7.

Table 7

Iohexol (wt%)	PoP (wt%)	HA (wt%)	Accel. (wt%)	Liquid/powder ratio
10	53.64	36	0.36	0.21/0.19/0.17
10	53.28	36	0.72	0.21
10	52.92	36	1.08	0.21
5	56.62	38	0.38	0.21
5	56.24	38	0.76	0.21
5	55.86	38	1.14	0.21
0	59.6	40	0.4	0.21
0	59.2	40	0.8	0.21
0	58.8	40	1.2	0.21

15

The final setting time for calcium sulfate hemihydrate and calcium phosphate based bone substitutes should preferably be less than 15 minutes.

- It was found that the setting time is dependent on
- 20       amount iohexol; an adding iohexol to calcium sulfate hemihydrate compositions increases the setting time. Furthermore, the setting time decreases with increased amount of accelerator.

- The results of the setting test with different
- 25       amounts of accelerator and iohexol as in Table 7 with a liquid/powder ratio of 0.21 are shown in Table 8 below.

Table 8

Io hexol (wt%)	Accel. (wt%)	Initial setting time (min)	Final setting time (min)
10	0.36	$6.8 \pm 0.5$	$13.4 \pm 0.6$
10	0.72	$5.8 \pm 0.2$	$12.9 \pm 0.4$
10	1.08	$5.5 \pm 0.3$	$12.7 \pm 0.5$
5	0.38	$5.4 \pm 0.2$	$11.2 \pm 0.4$
5	0.76	$5.0 \pm 0.5$	$10.2 \pm 0.4$
5	1.14	$4.6 \pm 0.2$	$9.3 \pm 0.8$
0	0.4	$4.9 \pm 0.3$	$9.0 \pm 0.5$
0	0.8	$4.0 \pm 0.3$	$7.2 \pm 0.4$
0	1.2	$3.3 \pm 0.1$	$6.1 \pm 0.4$

Even for calcium phosphates the setting time is in-  
 5 creased if io hexol is added. The more io hexol the longer  
 becomes the setting time, see Figure 3.

*Example 4. Compression test.*

The compressive strength is the maximum load a ma-  
 10 terial can withstand without breaking. An Instron 8511.20  
 mechanical test machine was used for determining the com-  
 pressive strength.

Paste from mixed powder and distilled water was  
 injected to a PTFE mould. 16 cylindrical samples with a  
 15 diameter of 4 mm and a height of about 8 mm were made.  
 Calcium phosphate samples were stored in 0,9 % saline  
 solution at a temperature of 37 °C for 14 days before  
 testing, while the samples of mixtures with calcium sulfate  
 were stored in air for 48 hours.

20 The samples were compressed vertically in the Instron  
 machine at a rate of 1 mm/min until they cracked. The com-  
 pressive strength C, was calculated as  $C = F/A$ , where  
 $F$  = Force (N) and  $A$  = cross section area ( $m^2$ ). The maximum  
 force was used as  $F$ .

25 It was found that the compression strength is not  
 dependent of the amount of accelerator and the compressive

strength of a calcium phosphate ceramic decreased when iohexol was added.

*Example 5. Density testing.*

5       The absorption of material in saline solution was investigated for calcium phosphate containing different amounts of iohexol or its dimer iodixanol. Materials containing iohexol or its dimer iodixanol had a lower density after 14 days than materials without the same. This means  
10   that these compounds are absorbed in the water and the porosity increases if either of them is added, a higher porosity can promote bone ingrowth.

*Example 6. Scanning Electron Microscope analysis.*

15       For the calcium sulfate based compositions it was impossible to see any difference in the structure if iohexol is added.

      The most important benefit with adding iohexol or its dimer iodixanol to calcium sulfates and calcium phosphates  
20   is the improved X-ray visibility. For example, adding 10 % iohexol can increase the chance of detecting any leakage when injected to the spine or hip, or at other locations. Complications can be avoided in this fashion. The increased injection time will make the injection easier and give the  
25   surgeon more time to work. The increased setting time is no problem because of the possibility to control it with changing the liquid/powder ratio or the amount of accelerator.

## CLAIMS

1. An artificial bone mineral substitute material,  
which comprises at least one ceramic and at least one water  
5 soluble non-ionic X-ray contrast agent.

2. An artificial bone mineral substitute material as  
in claim 1, c h a r a c t e r i z e d in that said least  
one ceramic is selected from the group comprising  
calcium sulfate  $\alpha$ -hemihydrate, calcium sulfate  $\beta$ -hemi-  
10 hydrate, calcium sulfate dihydrate, calcium carbonate,  $\alpha$ -  
tricalcium phosphate, hydroxyapatite, dicalcium phosphate  
dihydrate, anhydrous dicalcium phosphate, tetracalcium  
phosphate,  $\beta$ -tricalcium phosphate, calcium-deficient  
hydroxyapatite, monocalcium phosphate monohydrate,  
15 monocalcium phosphate, calcium pyrophosphate, precipitated  
hydroxyapatite, carbonated apatite (dahllite), octocalcium  
phosphate, amorphous calcium phosphate, oxyapatite, and  
carbonatoapatite.

3. An artificial bone mineral substitute material as  
20 in claim 1, c h a r a c t e r i z e d in that said least  
one water soluble non-ionic X-ray contrast agent is  
selected from the group comprising iohexol, iodixanol,  
ioversol, iopamidol, iotrolane, metrizamid, iodecimol,  
iogluocol, ioglucamide, ioglunide, iogulamide, iomeprol,  
25 iopentol, iopromide, iosarcol, iosimide, iotusal, ioxilane,  
iofrotal, and iodecol.

4. An artificial bone mineral substitute material as  
in any of claims 1-3, which further comprises at least one  
osteogenic factor.

30 5. A composition for an artificial bone mineral  
substitute material, which comprises at least one powdered  
ceramic, at least one water soluble non-ionic X-ray con-  
trast agent, and an aqueous liquid.

6. A composition as in claim 5, c h a r a c t e r -  
35 i z e d in that said at least one water soluble non-ionic  
X-ray contrast agent is dissolved in said aqueous liquid.

7. A composition as in claim 5, c h a r a c t e r -  
i z e d in that said at least one water soluble non-ionic  
X-ray contrast agent is a dry powder intermixed with said  
at least one powdered ceramic.

5 8. A composition as in claim 6 or 7, c h a r a c -  
t e r i z e d in that said at least one powdered ceramic  
is selected from the group comprising calcium sulfate  $\alpha$ -  
hemihydrate, calcium sulfate  $\beta$ -hemihydrate, calcium sulfate  
dihydrate, calcium carbonate,  $\alpha$ -tricalcium phosphate,  
10 hydroxyapatite, dicalcium phosphate dihydrate, anhydrous  
dicalcium phosphate, tetracalcium phosphate,  $\beta$ -tricalcium  
phosphate, calcium-deficient hydroxyapatite, monocalcium  
phosphate monohydrate, monocalcium phosphate, calcium  
pyrophosphate, precipitated hydroxyapatite, carbonated  
15 apatite (dahlite), octocalcium phosphate, amorphous calcium  
phosphate, oxyapatite, and carbonatoapatite.

9. A composition as in claim 8, c h a r a c t e r -  
i z e d in that said at least one powdered ceramic is a  
calcium sulfate hemihydrate.

20 10. A composition as in claim 9, c h a r a c t e r -  
i z e d in that said calcium sulfate hemihydrate is  
calcium sulfate  $\alpha$ -hemihydrate.

11. A composition as in claim 8, c h a r a c t e r -  
i z e d in that said at least one powdered ceramic is a  
25 calcium sulfate hemihydrate and at least one of  
hydroxyapatite and  $\beta$ -tricalcium phosphate.

12. A composition as in claim 11, c h a r a c -  
t e r i z e d in that said at least one of hydroxyapatite  
and  $\beta$ -tricalcium phosphate has a concentration between 20  
30 and 60 weight% of the total weight of the powder  
components.

13. A composition as in claim 8, c h a r a c t e r -  
i z e d in that said at least one powdered ceramic is a  
calcium sulfate hemihydrate and  $\alpha$ -tricalcium phosphate.

14. A composition as in claim 13, c h a r a c -  
t e r i z e d in that said calcium sulfate hemihydrate  
has a concentration between 1 and 30 weight% of the total  
weight of the powder components.

5 15. A composition as in claim 14, c h a r a c -  
t e r i z e d in that said  $\alpha$ -tricalcium phosphate has a  
concentration between 50 and 99 weight% of the total weight  
of the powder components.

16. A composition as in any of claims 9-15, which  
10 further comprises at least one accelerator.

17. A composition as in claim 16, c h a r a c -  
t e r i z e d in that said at least one accelerator  
is calcium sulfate dihydrate and/or disodium hydrogen  
phosphate.

15 18. A composition as in claim 17, c h a r a c -  
t e r i z e d in that said calcium sulfate dihydrate  
has a concentration between 0.1 and 10 weight% of the total  
weight of the powder components.

19. A composition as in any of claims 9-15, which  
20 further comprises vitamin E.

20. A composition as in claim 19, c h a r a c -  
t e r i z e d in that said vitamin E has a concentration  
between 0.1 and 10 weight% of the total weight of the  
powder components.

25 21. A composition as in any of claims 5-20,  
c h a r a c t e r i z e d in that said at least one water  
soluble non-ionic X-ray contrast agent is selected from the  
group comprising iohexol, ioversol, iopamidol, iotrolane,  
iodixanol, metrizamid, iodecimol, ioglucol, ioglucamide,  
30 ioglunide, iogulamide, iomeprol, iopentol, iopromide,  
iosarcol, iosimide, iotusal, ioxilane, iofrotal, and  
iodecol.

22. A composition as in claim 21, c h a r a c -  
t e r i z e d in that said at least one water soluble

non-ionic X-ray contrast agent is iohexol or its dimer iodixanol.

23. A composition as in claim 21 or 22, c h a r -  
a c t e r i z e d in that said at least one water soluble  
5 non-ionic X-ray contrast agent has a concentration between  
2 and 20 weight% of the total weight of the powder  
components.

24. A composition as in any of claims 5-23,  
c h a r a c t e r i z e d in that said aqueous liquid  
10 component is distilled water.

25. A composition as in any of claims 5-24,  
c h a r a c t e r i z e d in that the ratio between said  
powder components and said aqueous liquid component  
(liquid/powder ratio) is between 0.1 and 0.4 ml/g.

15 26. A composition as in any of claims 5-25, which  
further comprises at least one osteogenic factor.


27. Use of composition for an artificial bone mineral  
substitute material as in any of claims 5-26 as an X-ray  
contrast medium.

20 28. Use as in claim 27, said X-ray contrast medium  
being used as a means for monitoring the healing of bone  
defects and bone fractures.

29. Use as in claim 28, said X-ray contrast medium is  
to be applied adjacent to joints.


25

FIG 1




5

FIG 2



10

FIG 3



5

10

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/02428

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61L 27/02, A61L 27/10, A61L 24/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM.ABS.DATA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0639382 A1 (MIT PHARMACA AB), 22 February 1995 (22.02.95) --	1-3
Y	EP 0520690 A2 (NITTA GELATIN INC.), 30 December 1992 (30.12.92), page 4, line 13 - line 18, abstract, claims --	1-8, 21-29
Y	WO 9962570 A1 (BONE SUPPORT AB), 9 December 1999 (09.12.99), page 2, line 7 - line 22, abstract, claims --	1-29
Y	WO 9117722 A1 (LIFECORE BIOMEDICAL, INC.), 28 November 1991 (28.11.91) --	9-20

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

2 April 2003

Date of mailing of the international search report

04-04-2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Monika Bohlin/Elis

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/02428

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 0134216 A1 (CORIPHARM MEDIZINPRODUKTE GMBH & CO.KG), 17 May 2001 (17.05.01), page 7, line 17 - line 31; page 10, line 35 - page 11, line 31; page 13, line 34 - page 14, line 18, abstract, Claims --	1-29
Y	US 6251139 B1 (CHIH-I LIN ET AL), 26 June 2001 (26.06.01), column 1, line 33 - column 2, line 14, abstract, claims, examples 28-32 --	1-29
Y	US 6206957 B1 (FERDINAND C.M. DRIESSENS ET AL), 27 March 2001 (27.03.01), column 1 - column 2, line 55, abstract --	1-29
P,Y	WO 0205861 A1 (BONE SUPPORT AB), 24 January 2002 (24.01.02) --	1-29
A	DATABASE WPI Week 199433 Derwent Publications Ltd., London, GB; Class A 96, AN 1994-269325 & JP 61 99623 A (LION CORP et al), 19 July 1994 (1994-07-19) --	1-29
A	US 5650108 A (BERTHOLD NIESET ET AL), 22 July 1997 (22.07.97), column 3, line 15 - line 40, abstract, claims -- -----	1-29

## INTERNATIONAL SEARCH REPORT

Information on patent family members

28/02/03

International application No.

PCT/SE 02/02428

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
EP	0639382	A1	22/02/95	AT	221394 T	15/08/02
				CA	2129910 A	19/02/95
				DE	69431092 D	00/00/00
				SE	510491 C	31/05/99
				SE	9302672 A	19/02/95
EP	0520690	A2	30/12/92	DE	69205736 D, T	13/06/96
				JP	5168692 A	02/07/93
				JP	7034816 B	19/04/95
				US	5342441 A	30/08/94
WO	9962570	A1	09/12/99	AU	4664299 A	20/12/99
				AU	9659498 A	10/05/99
				EP	1025629 A	09/08/00
				EP	1079867 A	07/03/01
				SE	511087 C	02/08/99
				SE	9801901 A	02/08/99
				US	6403886 B	11/06/02
WO	9117722	A1	28/11/91	AU	7903391 A	10/12/91
				CA	2082632 A	12/11/91
				EP	0537180 A	21/04/93
				JP	5507862 T	11/11/93
WO	0134216	A1	17/05/01	DE	19953771 C	13/06/01
				EP	1227851 A	07/08/02
US	6251139	B1	26/06/01	NONE		
US	6206957	B1	27/03/01	DE	19816858 A	21/10/99
				EP	0950420 A	20/10/99
				JP	2000000295 A	07/01/00
WO	0205861	A1	24/01/02	AU	3064801 A	08/04/02
				AU	7120901 A	30/01/02
				SE	517168 C	23/04/02
				SE	0002676 A	18/01/02

# INTERNATIONAL SEARCH REPORT

Information on patent family members

28/02/03

International application No.

PCT/SE 02/02428

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	5650108	A	22/07/97	AT 191349 T	15/04/00
				AU 3300595 A	18/04/96
				BR 9504293 A	01/10/96
				CA 2159871 A	07/04/96
				CN 1127700 A	31/07/96
				CZ 9502574 A	17/04/96
				DE 4435680 A	11/04/96
				DE 59508127 D	00/00/00
				DK 705609 T	21/08/00
				EP 0705609 A,B	10/04/96
				SE 0705609 T3	
				ES 2146689 T	16/08/00
				JP 8117322 A	14/05/96
				PL 310793 A	15/04/96
				ZA 9508407 A	08/05/96